To assess the efficacy of intraventricular thrombosis in patients with intraventricular hemorrhage (IVH).
- Tissue plasminogen activator (Activase®)Drug
Intervention Desc: Thrombolytic
Prospective, randomized, double-blinded, placebo-controlled, multicenter clinical trial.
All patients will undergo EVD. Patients in the treatment group will also receive 1-3 mg r-tPA injected into the ventricles 1 hour before the commencement of drainage, and twice daily thereafter. Patients in the placebo group will receive injections of Ringer's lactate on the same time scale. Participants will receive daily head CT scans during the acute treatment phase, and again between days 28 and 32.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Percent rate of intraventricular blood clot resolution.|
|Secondary||Duration of external ventricular drainage, degree and incidence of communicating hydrocephalus at 30 days.|